Pharmacogenomics (PGx) APOE Test
A targeted pharmacogenomic test evaluating APOE status to guide appropriate prescription of lecanemab-irmb and donanemab-azbt, powered by the Helix Exome+® platform.
6-9 days
≤ 5 minutes
Test Description
Lecanemab-irmb and donanemab-azbt are prescribed for patients with mild cognitive impairment (MCI) or mild dementia stage of Alzheimer's disease (AD) in order to slow the progression of MCI due to AD and mild AD dementia. APOE ε4 homozygotes have an increased risk for adverse events.
This test evaluates a patient’s APOE status, which can aid in appropriate prescription of lecanemab-irmb and donanemab-azbt.
Have Questions
Our team is available Monday through Friday, 9am-5pm Pacific Time.
Indications for Testing
Patients for whom lecanemab-irmb or donanemab-azbt treatments are being considered.
Methodology
This test utilizes next-generation sequencing to determine APOE status.
Technical Specifications
APOE: rs429358 and rs7412 (e2, e3, e4)
E2/E4 and E1/E3 genotypes cannot be distinguished by this assay and are reported as E2/E4. E1 genotypes are reported as Indeterminate....
Genes Tested
Showing 1 of 1 genes in this panel